How are secondary forms of Focal segmental glomerulosclerosis treated?
Treatment of the secondary forms of Focal segmental glomerulosclerosis is directed at the underlying disease.
Resolution of Focal segmental glomerulosclerosis manifestations can occur with weight loss in obesity-related glomerulopathy and following heart transplantation in cyanotic heart disease–associated Focal segmental glomerulosclerosis.
Mitochondrial dysfunction in animal models of obesity-related glomerulopathy is modifiable by mitochondrial-targeted antioxidants.
Human investigations are needed to assess whether these findings can be translated to humans safely and effectively.
In addition, therapies such as ACE inhibitors, ARBs, and lipid-lowering agents may be prescribed with a goal of reducing proteinuria, controlling blood pressure, and minimizing further cardiovascular or kidney insults.
